STUART, Fla., Jan. 21, 2025 /PRNewswire/ — Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases, today announced last patient last visit in the phase III study of its lead therapeutic candidate ST-100…
